[{"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31 30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Sven Ante Lundberg M.D.", "age": 61, "title": "CEO, President & Executive Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1114527, "exercisedValue": 0, "unexercisedValue": 10252539}, {"maxAge": 1, "name": "Mr. Gregory D. Perry", "age": 64, "title": "Chief Financial Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 419102, "exercisedValue": 0, "unexercisedValue": 801494}, {"maxAge": 1, "name": "Mr. Peter B. Silverman J.D.", "age": 46, "title": "EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 781842, "exercisedValue": 565022, "unexercisedValue": 1331558}, {"maxAge": 1, "name": "Dr. Hennie  Hoogenboom", "title": "Co-Founder and Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Harry  Shuman", "title": "Chief Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cornelis Adriaan de Kruif Ph.D.", "age": 59, "title": "CTO & Executive VP", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 336672, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.", "title": "Chief Scientific Officer & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathleen  Farren", "title": "IR & Corporate Communications Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Audrey  Bergan", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shannon  Campbell", "age": 58, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 46.22, "open": 44.5, "dayLow": 44.5, "dayHigh": 47.67, "regularMarketPreviousClose": 46.22, "regularMarketOpen": 44.5, "regularMarketDayLow": 44.5, "regularMarketDayHigh": 47.67, "payoutRatio": 0.0, "forwardPE": -12.074359, "volume": 814676, "regularMarketVolume": 814676, "averageVolume": 623450, "averageVolume10days": 703170, "averageDailyVolume10Day": 703170, "bid": 47.02, "ask": 47.61, "bidSize": 7, "askSize": 7, "marketCap": 3253471488, "fiftyTwoWeekLow": 37.77, "fiftyTwoWeekHigh": 61.61, "priceToSalesTrailing12Months": 90.04156, "fiftyDayAverage": 42.1083, "twoHundredDayAverage": 48.926575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2726355200, "profitMargins": 0.0, "floatShares": 59106896, "sharesOutstanding": 69090496, "sharesShort": 6635045, "sharesShortPriorMonth": 7999941, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.09689999, "heldPercentInsiders": 0.020469999, "heldPercentInstitutions": 1.06581, "shortRatio": 13.37, "shortPercentOfFloat": 0.0975, "impliedSharesOutstanding": 69090496, "bookValue": 9.414, "priceToBook": 5.002125, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -215326000, "trailingEps": -3.35, "forwardEps": -3.9, "enterpriseToRevenue": 75.453, "enterpriseToEbitda": -10.113, "52WeekChange": -0.07615429, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 47.09, "targetHighPrice": 109.0, "targetLowPrice": 67.0, "targetMeanPrice": 86.1875, "targetMedianPrice": 86.5, "recommendationMean": 1.27778, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 16, "totalCash": 537027008, "totalCashPerShare": 7.773, "ebitda": -269596000, "totalDebt": 9912000, "quickRatio": 6.182, "currentRatio": 6.535, "totalRevenue": 36133000, "debtToEquity": 1.53, "revenuePerShare": 0.563, "returnOnAssets": -0.27466, "returnOnEquity": -0.42882, "grossProfits": 36133000, "freeCashflow": -169050880, "operatingCashflow": -185835008, "revenueGrowth": 0.022, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -9.69934, "financialCurrency": "USD", "symbol": "MRUS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Merus N.V.", "longName": "Merus N.V.", "exchange": "NGM", "messageBoardId": "finmb_24929296", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1740779724, "regularMarketTime": 1740776401, "regularMarketChangePercent": 1.8822995, "regularMarketPrice": 47.09, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1463664600000, "postMarketChangePercent": 0.0, "postMarketPrice": 47.09, "postMarketChange": 0.0, "regularMarketChange": 0.86999893, "regularMarketDayRange": "44.5 - 47.67", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 623450, "fiftyTwoWeekLowChange": 9.32, "fiftyTwoWeekLowChangePercent": 0.24675667, "fiftyTwoWeekRange": "37.77 - 61.61", "fiftyTwoWeekHighChange": -14.52, "fiftyTwoWeekHighChangePercent": -0.23567604, "fiftyTwoWeekChangePercent": -7.615429, "earningsTimestamp": 1740690640, "earningsTimestampStart": 1746529140, "earningsTimestampEnd": 1747051200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.35, "epsForward": -3.9, "epsCurrentYear": -3.848, "priceEpsCurrentYear": -12.237526, "fiftyDayAverageChange": 4.981701, "fiftyDayAverageChangePercent": 0.11830687, "twoHundredDayAverageChange": -1.8365746, "twoHundredDayAverageChangePercent": -0.037537362, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Merus", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]